Skip to main content

Table 1 Characteristics of schizophrenia trials conducted in Africa

From: Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?

  STUDIES (n = 38) No %
Type of comparison
Typical AP versus typical AP 12 (31.58)
Typical AP versus placebo 3 (7.89)
Typical AP versus no treatment 1 (2.63)
Typical AP versus atypical AP 6 (15.79)
Atypical AP versus atypical AP 4 (10.53)
Other pharmacological interventions 7 (18.42)
Non pharmacological interventions 5 (13.16)
Year of publication
1970–1985 9 (23.68)
1986–2000 9 (23.68)
2001–2010 20 (52.64)
Sample size
Min-20 4 (10.81)
21–40 12 (32.43)
41–60 10 (27.03)
61-Max 11 (29.73)
Arms
Two arms 34 (89.47)
Three arms or more 4 (10.53)
Weeks of follow-up
< 6 weeks 16 (42.43)
6–12 weeks 9 (24.24)
13–24 weeks 7 (18.18)
> 24 weeks 6 (15.15)
Blinding
Open label 6 (15.79)
Single blind 7 (18.42)
Double blind 18 (47.37)
Unclear 7 (18.42)
Diagnostic criteria
Unclear 9 (23.68)
DSM† − ICD†† 25 (65.79)
Clinical diagnosis 4 (10.53)
Number of outcomes
Min-5 13 (34.21)
6–10 14 (36.84)
11-Max 11 (28.95)
Ethics committee approval
Unclear 16 (42.11)
Yes 22 (57.89)
Sponsor (drug company)
Unclear 20 (52.63)
Yes 15 (39.48)
Independent study 3 (7.89)